Novel patient-derived 3D (PD3D) cell models and matched patient-derived xenografts (PDX) from peritoneal metastasis of colorectal cancer for drug testing and biomarker analysis
Metastasis formation occurring in single or multiple organs is the most lethal feature of colorectal cancer (CRC). Peritoneum (PM) is the third most common site of metastasis of CRC following by liver and lung, and patients with diagnosed PMCRC have significantly worse survival than patients with non-peritoneal disease sites. PM-CRC is usually diagnosed at advanced stages and unfortunately there are not specific and efficient treatment options. Although the delivery of chemotherapeutics to the abdomen is emerging (HIPEC/PIPAC) as a therapeutic strategy, there is still a strong clinical need of biomarkers for patient stratification, diagnosis, prognosis, and therapy prediction of PM-CRC. Moreover, the development of reliable in vitro and in vivo models of PM-CRC is crucial for the evaluation of novel therapeutic options like targeted therapy or combination therapies.
Rapid generation of phenomicand functional profiles of patient-derived 3D cell culture models for identification of treatment vulnerabilities of breast cancer. Early results of the EFRE-PoPproject.
Targeted treatment for breast cancer subsets currently relies on the occurrence of estrogen, progesterone and Her2/neu receptors. For triple negative breast cancer (TNBC) there is no identified targeted therapy and treatment relies on chemotherapy. The mutational landscape for breast cancer subsets has been characterized, but drug development has been limited due to the lack of appropriate preclinical models. Development of patient-derived preclinical models has been difficult so far. Our aim is to establish a series of patientderived 3D (PD3D) cell culture models as a versatile resource for ex vivo drug sensitivity screens as well as secondary establishment of PDX.